2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

European Heart Journal - Tập 37 Số 1 - Trang 67-119 - 2016
Nazzareno Galiè, Marc Humbert, Jean-Luc Vachiéry, Simon Gibbs, Iréne Lang, Adam Torbicki, Gérald Simonneau, Andrew J. Peacock1,2,3,4, Anton Vonk Noordegraaf1,2,3,4, Maurice Beghetti1,2,3,4, Hossein A. Ghofrani1,2,3,4, Miguel Ángel Gómez Sánchez, Georg Hansmann, Walter Klepetko5,6, Patrizio Lancellotti, Marco Matucci, Theresa McDonagh, Luc Piérard, Pedro T. Trindade, Maurizio Zompatori7, Marius M. Hoeper1,2,3,4
1(ERS Chairperson) (France), Jean-Luc Vachiery c (Belgium),
2Spain
3He ´ctor Bueno (Spain), Robert A. Byrne (Germany), Scipione Carerj (Italy), Grac ¸a Castro (Portugal)
4He ´le `ne Bouvaist (France),
5(Canada), Bernard Iung (France),
6(USA), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland),
7France

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/j.jacc.2013.10.032

10.1183/09031936.00145608

10.1183/09031936.00021915

10.1016/j.jacc.2013.10.033

Simonneau G Galiè N Rubin LJ Langleben D Seeger W Domenighetti G Gibbs S Lebrec D Speich R Beghetti M . Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(Suppl 1):S5–S12.

10.1016/j.jacc.2013.10.029

10.1136/adc.2009.180091

10.1016/j.clp.2011.12.006

10.1016/j.jacc.2013.10.028

10.1164/rccm.200510-1668OC

10.1183/09031936.00092306

McGoon MD Benza RL Escribano-Subias P Jiang X Miller DP Peacock AJ Pepke-Zaba J Pulido T Rich S Rosenkranz S Suissa S Humbert M . Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013;62(Suppl):D51–D59.

Simonneau G Robbins I Beghetti M Channick RN Delcroix M Denton CP Elliott CG Gaine S Gladwin MT Jing ZC Krowka MJ Langleben D Nakanishi N Souza R . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl):S43–S54.

10.1161/CIRCULATIONAHA.111.079921

10.1183/09031936.00188611

10.1183/09031936.00057914

Badesch BD Champion HC Gomez-Sanchez MA Hoeper M Loyd J Manes A McGoon M Naeije R Olschewski H Oudiz R Torbicki A . Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl):S55–S56.

10.1016/j.ccm.2006.12.001

10.1093/eurheartj/ehs109

Seeger W Adir Y Barberà JA Champion H Coghlan JG Cottin V De Marco T Galiè N Ghio S Gibbs S Martinez FJ Semigran MJ Simonneau G Wells AU Vachiéry JL . Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013;62(Suppl):D109–D116.

10.1183/09031936.00079512

10.1183/09031936.05.00021005

10.1183/09031936.00101211

10.1056/NEJMoa032274

10.1161/CIRCULATIONAHA.110.015008

Soubrier F Chung WK Machado R Grunig E Aldred M Geraci M Loyd JE Elliott CG Trembath RC Newman JH Humbert M . Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(Suppl):D13–D21.

10.1056/NEJMoa1211097

Eyries, 2014, EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension, Nat Genet, 46, 65, 10.1038/ng.2844

10.1161/01.CIR.0000091409.53101.E8

10.1183/09031936.00089610

10.1016/j.ijcard.2012.03.071

10.1378/chest.10-3331

10.1016/j.ijcard.2012.06.024

10.7326/0003-4819-107-2-216

10.1148/rg.324125021

10.1183/09031936.00184412

10.1016/S0735-1097(02)02964-9

10.1183/09031936.00134506

10.1183/09031936.05.00035205

10.1159/000110207

10.1378/chest.11-3124

10.1378/chest.120.3.894

10.1016/j.echo.2010.05.010

10.1093/ehjci/jev014

10.1136/hrt.56.1.33

10.1002/art.21433

10.2967/jnumed.106.039438

Meng, 2013, [A comparison of ventilation/perfusion single photon emission CT and CT pulmonary angiography for diagnosis of pulmonary embolism], Zhonghua Jie He He Hu Xi Za Zhi, 36, 177

10.1136/thoraxjnl-2012-203020

10.1136/thoraxjnl-2014-206088

10.1097/MD.0000000000000256

10.1378/chest.113.5.1250

10.2214/ajr.183.1.1830065

10.1183/09031936.04.00079704

Reichelt, 2008, Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography, Eur J Radiol, 71, 49, 10.1016/j.ejrad.2008.03.016

10.1056/NEJMra010902

10.1183/09031936.00012914

10.1053/j.sult.2012.05.001

10.1016/j.jvir.2008.07.011

10.1183/09059180.00006313

10.1186/1532-429X-14-40

10.1016/j.jcmg.2013.01.013

10.1007/s00330-003-1878-8

10.1093/eurheartj/ehl477

10.1161/CIRCIMAGING.113.000629

10.1016/j.jacc.2011.06.068

10.1016/S0140-6736(98)06373-9

Naeije, 2003, Hepatopulmonary syndrome and portopulmonary hypertension, Swiss Med Wkly, 133, 163

10.1016/j.jacc.2006.07.061

Kovacs, 2014, Reading pulmonary vascular pressure tracings, How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med, 190, 252, 10.1164/rccm.201402-0269PP

10.1164/ajrccm.160.2.9811062

10.1378/chest.11-1387

10.1016/S0140-6736(11)60101-3

10.1161/CIRCHEARTFAILURE.109.867044

10.1161/CIRCULATIONAHA.112.111302

10.1183/09031936.00091212

10.1161/CIRCHEARTFAILURE.113.000468

10.1161/CIRCHEARTFAILURE.109.930701

10.1111/j.1752-699X.2012.00310.x

10.1378/chest.08-2784

10.1183/09031936.00074312

10.1183/09031936.00009008

10.1016/j.healun.2013.11.008

10.1056/NEJM199207093270203

10.1161/CIRCULATIONAHA.104.488486

Barst R McGoon M Torbicki A Sitbon O Krowka MJ Olschewski A Gaine S . Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(Suppl 1):S40–S47.

10.1161/01.CIR.84.3.1145

10.1378/chest.107.1.54

10.1016/S0735-1097(99)00494-5

Opitz, 2003, Assessment of the vasodilator response in primary pulmonary hypertension, Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J, 24, 356

10.1016/j.jacc.2013.10.024

10.1183/09031936.00090608

10.1097/MNM.0b013e32835085d9

10.1183/09031936.00038709

10.4065/84.7.586

10.1016/S0735-1097(02)02012-0

10.1183/09031936.00092311

10.1378/chest.12-2417

10.1161/CIRCULATIONAHA.109.898122

10.1183/09031936.05.00054804

10.1378/chest.10-2015

10.1016/S0735-1097(02)01744-8

10.1067/mje.2002.123962

10.1164/rccm.200604-547OC

10.1183/09031936.00072709

10.1161/01.CIR.0000022687.18568.2A

10.1161/01.CIR.0000029100.82385.58

10.1161/CIRCIMAGING.113.000640

10.1016/j.echo.2010.06.029

10.1016/j.jacc.2014.01.084

10.1161/CIRCULATIONAHA.113.001573

10.1007/s00330-011-2306-0

10.1161/CIRCIMAGING.113.000338

10.1136/thx.2005.040618

10.1183/09031936.00102212

10.1016/j.jacc.2012.01.083

10.1161/CIRCULATIONAHA.112.105890

10.1378/chest.12-0270

10.1183/09031936.01.17406470

10.1183/09031936.06.00042705

10.1161/hc2901.093198

10.1016/j.ijcard.2012.03.135

10.1093/eurjhf/hft044

10.1161/CIRCULATIONAHA.104.529800

10.1016/j.healun.2009.09.003

10.1096/fj.04-3223fje

10.1161/01.ATV.0000168414.06853.f0

10.1161/01.CIR.0000105764.22626.B1

10.1378/chest.128.4.2355

10.1093/eurheartj/ehq226

10.1378/chest.120.5.1562

10.1016/j.jacc.2008.12.038

10.1164/rccm.2106007

10.1164/ajrccm.165.4.2012112

10.1164/ajrccm.151.5.7735624

10.1161/01.CIR.102.8.865

10.1378/chest.06-1758

10.1378/chest.129.5.1313

10.1161/01.CIR.0000084544.54513.E2

10.1164/rccm.200802-235OC

10.1164/ajrccm.160.2.9812078

10.1378/chest.10-1146

10.1183/09031936.00160307

10.1183/09031936.05.00075305

McLaughlin VV Gaine SP Howard LS Leuchte HH Mathier MA Mehta S Palazzini M Park MH Tapson VF Sitbon O . Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013;62(Suppl):D73–D81.

10.1093/eurheartj/ehp022

10.1159/000334431

Galiè N Simonneau G . The Fifth World Symposium on Pulmonary Arterial Hypertension. J Am Coll Cardiol 2013;62(Suppl):D1–D3.

Galiè N Corris P Frost A Girgis R Granton J Jing ZC Klepetko W McGoon M McLaughlin VV Preston RJ Rubin LJ Sandoval J Seeger W Keogh AM . Updated treatment algorithm of pulmonary hypertension. J Am Coll Cardiol 2013;62(Suppl):D60–D72.

10.1097/01.psy.0000145593.37594.39

10.1093/eurheartj/ehp297

10.1161/CIRCULATIONAHA.106.618397

10.1183/09031936.00027909

10.1159/000322475

10.1186/ar3883

10.1183/09031936.00123711

10.1016/j.ijcard.2012.09.036

10.1016/j.rmed.2013.02.006

10.1378/chest.12-0993

10.1183/09031936.00141211

10.1378/chest.12-0528

10.1783/147118906776276486

10.1097/01.AOG.0000164074.64137.f1

10.1097/00000542-200506000-00012

10.1183/09031936.00089212

10.1034/j.1399-6576.2001.450220.x

10.1016/0952-8180(96)00084-0

10.1183/09059180.00005713

Weitzenblum, 1985, Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease, Am Rev Respir Dis, 131, 493, 10.1164/arrd.1985.131.4.493

10.1183/09031936.00185011

10.1161/01.CIR.70.4.580

10.1016/S0272-5231(05)70283-5

10.1183/09031936.98.12061446

10.1164/ajrccm.150.4.7921465

10.1161/CIRCULATIONAHA.113.004526

10.1093/eurheartj/ehs402

Preston, 2014, Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL), Am J Respir Crit Care Med, 189, A2464

10.1016/S0002-9343(01)00915-9

10.1164/ajrccm.164.9.2106076

10.1378/chest.114.3.787

10.1183/09031936.00100510

10.1093/rheumatology/ket331

10.1016/j.jacc.2006.03.040

10.1016/j.jacc.2011.02.057

10.1093/eurheartj/ehr130

10.1016/j.ijcard.2014.04.233

10.1016/S0002-9149(99)80384-1

10.1136/ard.62.11.1088

10.1093/eurheartj/ehq170

10.1056/NEJM199306173282402

10.7326/0003-4819-114-6-464

10.1016/j.cardiores.2003.11.026

10.1016/j.jacc.2005.04.050

10.1161/CIRCULATIONAHA.107.742510

10.1378/chest.08-1028

10.1016/S0140-6736(01)06250-X

10.1056/NEJMoa012212

10.1183/09031936.04.00028404

10.1016/S0140-6736(08)60919-8

10.1161/CIRCULATIONAHA.106.630715

10.1056/NEJMoa1213917

10.1164/rccm.200411-1587OC

10.1007/s00395-004-0504-5

10.1016/j.jacc.2004.06.060

10.1056/NEJMoa050010

10.1016/j.jacc.2003.10.056

10.1093/eurheartj/ehq011

Singh, 2006, A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension, Am Heart J, 151, 851, 10.1016/j.ahj.2005.09.006

10.7326/0003-4819-149-8-200810210-00004

10.1111/j.1365-2125.2010.03831.x

10.1161/CIRCULATIONAHA.108.839274

10.1164/rccm.201101-0093OC

10.1056/NEJM199507273330403

10.1056/NEJMoa1209655

10.1183/09031936.00105914

Jones, 1995, Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades, Mol Pharmacol, 48, 890

10.1007/BF03256644

10.1016/S0735-1097(02)01786-2

10.1016/S0735-1097(03)00463-7

Rubin, 1990, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol), Results of a randomized trial. Ann Intern Med, 112, 485, 10.7326/0003-4819-112-7-485

10.1056/NEJM199602013340504

Badesch, 2000, Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease, A randomized, controlled trial [see comments]. Ann Intern Med, 132, 425

10.1161/01.CIR.99.14.1858

10.1002/hep.510300307

10.1164/rccm.200204-330OC

10.1016/j.healun.2006.12.014

Doran, 2008, Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension, Int J Clin Pract Suppl, 160, 5, 10.1111/j.1742-1241.2008.01811.x

10.1016/j.ahj.2013.08.007

10.1056/NEJMoa020204

10.1164/rccm.200603-358OC

Hoeper, 2006, Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension, Eur Respir J, 4, 691, 10.1183/09031936.06.00057906

10.1136/hrt.80.2.151

10.1164/ajrccm.165.6.2106079

10.1016/j.healun.2009.09.005

10.1378/chest.129.3.683

10.1097/FJC.0b013e31802b3184

10.1016/j.jacc.2010.01.027

10.1378/chest.11-2212

10.1378/chest.12-2875

10.1161/CIRCULATIONAHA.112.124388

10.1183/09031936.00137511

10.1016/j.jacc.2013.05.075

10.1016/j.jacc.2013.06.032

10.1093/eurheartj/ehq152

10.1016/j.healun.2011.11.002

10.1183/09031936.00116313

Galiè, 2015, Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension, New Engl J Med, 379, 834, 10.1056/NEJMoa1413687

McLaughlin VV Channick R Chin KM Frey A Gaine S Ghofrani A Hoeper M Lang I Preiss R Rubin LJ Simonneau G Sitbon O Stefani M Tapson V Galiè N . Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J Am Coll Cardiol 2015;65(Suppl A):A380.

10.1111/j.1755-5922.2011.00279.x

10.1093/eurheartj/ehi728

10.1183/13993003.02044-2014

10.1183/09031936.00209914

Sandoval, 1998, Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension, A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol, 32, 297

10.1378/chest.06-1227

10.1378/chest.07-1222

Keogh A Benza RL Corris P Dartevelle P Frost A Kim NH Lang I Pepke-Zaba J Sandoval J Mayer E . Interventional and surgical modalities of treatment in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl):S67–S77.

10.1183/09031936.00070209

10.1097/01.CCM.0000280433.74246.9E

10.1186/cc9264

10.1164/rccm.201104-0662CI

10.1097/MAT.0000000000000021

10.1111/j.1600-6143.2010.03192.x

10.1164/rccm.201109-1599OC

10.1016/j.healun.2011.03.002

10.1111/j.1600-6143.2009.02549.x

10.1016/j.healun.2006.06.001

10.1016/j.athoracsur.2008.05.049

10.1016/j.ejcts.2010.02.039

10.1016/j.jtcvs.2011.08.055

Christie JD Edwards LB Kucheryavaya AY Benden C Dipchand AI Dobbels F Kirk R Rahmel AO Stehlik J Hertz MI . The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report—2012. J Heart Lung Transplant 2012;31:1073–1086.

10.1016/S1053-2498(01)00420-X

10.1016/j.jtcvs.2004.07.058

10.1002/sim.5403

10.1377/hlthaff.24.1.67

10.1016/j.ahj.2006.09.008

10.1164/ajrccm.165.3.200109-0130c

10.1016/j.ijcard.2011.02.059

10.1378/chest.10-1134

10.1378/chest.11-2794

10.1136/heartjnl-2011-301132

10.4187/respcare.02252

10.1002/ccd.22592

10.1183/09031936.00056110

10.1161/CIRCULATIONAHA.111.026591

10.1161/CIRCULATIONAHA.110.969584

10.1136/hrt.2009.182378

10.1016/S0140-6736(11)61621-8

10.1183/09031936.00065713

10.4103/2045-8932.83456

10.1183/09031936.00140112

10.1183/09059180.00008510

10.4103/2045-8932.109931

10.1136/hrt.2006.096412

10.1161/01.CIR.99.9.1197

10.1016/j.jpeds.2010.09.025

10.1016/j.jacc.2007.09.031

10.1016/S0009-9236(03)00005-5

10.1016/j.jacc.2005.01.066

10.1111/j.1365-2125.2009.03532.x

10.1161/CIRCULATIONAHA.110.016667

10.1161/CIRCULATIONAHA.113.005698

10.1007/s00246-012-0180-4

10.1136/heartjnl-2013-304895

10.1136/hrt.2005.077669

10.1161/CIRCINTERVENTIONS.112.000091

10.1093/ejcts/ezu445

10.1016/j.healun.2013.01.1049

10.1183/09031936.00030414

10.2165/00003495-200868080-00004

10.1136/hrt.2006.098848

10.1016/j.jacc.2008.11.025

Daliento, 1998, Eisenmenger syndrome, Factors relating to deterioration and death. Eur Heart J, 19, 1845

Hopkins, 1996, Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome, J Heart Lung Transplant, 15, 100

10.1093/eurheartj/eht072

10.1097/00019501-200502000-00004

10.1161/CIRCULATIONAHA.105.592386

10.1016/0002-9149(91)90284-R

van Albada, 2008, Pulmonary arterial hypertension in congenital cardiac disease—the need for refinement of the Evian-Venice classification, Cardiol Young, 18, 10, 10.1017/S1047951107001849

10.1017/S1047951108003260

Lopes AA Leary PW . Measurement, interpretation and use of hemodynamic parameters. Cardiol Young 2009;19(Suppl 1):8–12.

10.1016/j.jacc.2007.04.056

Gatzoulis, 2007, Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study, Int J Cardiol, 127, 27, 10.1016/j.ijcard.2007.04.078

10.1016/j.amjcard.2010.12.051

10.1161/CIRCULATIONAHA.105.603001

10.1002/art.38172

10.1016/j.lpm.2014.06.007

10.1136/annrheumdis-2013-203301

10.1002/art.30541

10.1183/09031936.00182813

10.1093/rheumatology/ken488

10.3899/jrheum.100245

10.1002/art.34501

10.1183/09031936.00025413

10.1183/09031936.00057010

10.1002/art.22069

10.1136/annrheumdis-2012-202489

O'Callaghan, 2011, Pulmonary veno-occlusive disease: the bete noire of pulmonary hypertension in connective tissue diseases, Presse Med, 40, e65

Demling, 1981, Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep, Am J Physiol, 240, H348

10.1002/art.23303

10.1136/ard.2007.077149

10.1016/j.lpm.2014.01.020

10.1016/S0140-6736(04)16107-2

Zopey, 2013, Transition from hepatopulmonary syndrome to portopulmonary hypertension: a case series of 3 patients, Case Rep Pulmonol, 2013, 561870

10.1002/hep.21431

10.1002/hep.22275

10.1164/rccm.200809-1472OC

10.1378/chest.11-0160

10.1164/rccm.200804-613OC

10.1053/j.gastro.2005.10.013

10.1183/09031936.00032407

10.1055/s-0031-1273393

10.1183/09031936.06.00030206

10.1097/00007890-199702270-00020

10.1111/j.1600-6143.2008.02384.x

10.1111/j.1432-2277.2008.00830.x

10.1183/09031936.00117511

10.1183/09031936.00138706

10.1111/ajt.12385

10.1053/jlts.2000.6356

10.1111/j.1600-6143.2006.01701.x

Raevens, 2013, Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation, Eur J Gastroenterol Hepatol, 25, 495, 10.1097/MEG.0b013e32835c504b

10.1097/00007890-199802270-00001

10.1002/lt.21310

10.1097/TP.0b013e3181636f3f

10.1016/S0735-1097(10)80121-4

10.1136/hrt.2005.076794

10.1097/QAD.0b013e328331c65e

Opravil, 1997, HIV-associated primary pulmonary hypertension, A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med, 155, 990

10.1164/rccm.200704-541OC

10.1164/rccm.200404-445OC

10.1097/MD.0b013e31818193bb

10.1097/01.pas.0000209834.69972.e5

10.1164/ajrccm.157.5.9708065

10.1164/ajrccm.162.5.9912045

10.7326/0003-4819-109-2-106

10.1378/chest.13-2366

10.1183/09031936.00097911

10.1183/09031936.06.00054105

10.1183/09031936.00017809

10.1016/j.healun.2012.06.002

10.1016/S0735-1097(00)01102-5

10.1161/CIRCHEARTFAILURE.110.958801

10.1378/chest.08-2008

10.1016/j.jacc.2011.06.076

10.1378/chest.12-1653

10.1161/01.CIR.102.14.1718

10.1016/S0002-9149(01)01864-1

10.1016/j.jchf.2013.05.001

10.1016/j.jchf.2014.07.010

10.1378/chest.13-1510

10.1016/j.jchf.2014.09.002

McMurray, 2012, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 33, 1787

10.1016/j.ahj.2009.02.022

10.1016/j.athoracsur.2008.05.016

10.1016/j.healun.2009.05.030

10.1016/j.hfc.2012.04.009

10.1161/CIRCULATIONAHA.113.001458

Oswald-Mammosser, 1995, Prognostic factors in COPD patients receiving long-term oxygen therapy, Importance of pulmonary artery pressure. Chest, 107, 1193

10.1164/ajrccm.164.2.2006129

10.1378/chest.129.3.746

10.1378/chest.127.5.1531

10.1164/rccm.200401-006OC

10.1164/rccm.200210-1130OC

10.1164/rccm.200811-1691OC

10.1016/j.rmed.2008.03.022

10.1378/chest.97.2.268

10.1016/S0140-6736(96)90011-2

10.1056/NEJM198106253042606

10.1186/1465-9921-6-88

10.1097/00005344-199803000-00006

10.1183/09031936.00011308

10.1164/rccm.200907-0988OC

10.1056/NEJMoa1002110

10.1183/09031936.00176312

10.3109/15412555.2011.651180

10.1016/S2213-2600(14)70013-X

10.1183/09031936.00049312

Guerin, 2014, Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism, Prevalence of CTEPH after pulmonary embolism. Thromb Haemost, 112, 598, 10.1160/TH13-07-0538

10.1183/09031936.00201612

10.1016/j.jtcvs.2010.07.010

10.1183/09031936.00181212

10.1160/TH13-02-0097

10.1016/j.jcmg.2010.09.013

10.1161/CIRCULATIONAHA.105.602565

10.2214/ajr.169.1.9207504

10.1007/s00330-011-2290-4

10.1007/s11604-014-0319-8

10.7326/0003-4819-103-6-844

10.1136/thoraxjnl-2013-203746

10.1016/j.jtcvs.2010.11.024

10.1016/j.athoracsur.2012.04.004

10.1183/09059180.00009211

10.1016/S0140-6736(11)61144-6

10.1016/j.athoracsur.2006.07.020

10.1016/j.athoracsur.2008.06.037

10.1016/j.athoracsur.2011.05.035

10.1183/09031936.06.00135905

10.1111/j.1538-7836.2007.02394.x

10.1183/09031936.00039007

10.1016/j.jacc.2008.08.059

10.1056/NEJMoa1209657

10.1016/j.jtcvs.2009.03.053

10.1161/01.CIR.103.1.10

10.1161/CIRCINTERVENTIONS.112.971390

10.1161/CIRCINTERVENTIONS.112.971077

10.1253/circj.CJ-11-1217

10.1016/j.jcin.2013.03.009

10.1136/heartjnl-2012-303549

10.1513/pats.200605-111LR

10.1136/bmj.300.6727.763

2001, Recommendations on the management of pulmonary hypertension in clinical practice, Heart, 86, I1

10.1136/thx.2007.090480

10.1157/13116205

10.1136/bmjopen-2011-000806

Ghofrani HA Distler O Gerhardt F Gorenflo M Grunig E Haefeli WE Held M Hoeper MM Kahler CM Kaemmerer H Klose H Kollner V Kopp B Mebus S Meyer A Miera O Pittrow D Riemekasten G Rosenkranz S Schranz D Voswinckel R Olschewski H . Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011;154(Suppl 1):S20–S33.

10.1183/09059180.00005412